Arpan Mohanty1, Sarah Salameh2, Adeel A Butt3,4,5,6. 1. Boston University School of Medicine, Boston, MA, USA. 2. Hamad Medical Corporation, Doha, Qatar. 3. Hamad Medical Corporation, Doha, Qatar. aab2005@qatar-med.cornell.edu. 4. VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. aab2005@qatar-med.cornell.edu. 5. Weill Cornell Medical College, New York, NY, USA. aab2005@qatar-med.cornell.edu. 6. Weill Cornell Medical College, Doha, Qatar. aab2005@qatar-med.cornell.edu.
Abstract
PURPOSE OF REVIEW: Direct acting antiviral agents (DAAs) have emerged as simple, short, safe, and effective treatments for chronic hepatitis C (CHC) infection. CHC is a systemic disease with frequent and multiple extrahepatic manifestations. The beneficial effects of DAA treatment regimens extend beyond improvement in liver-related outcomes to amelioration of extra hepatic manifestations and are likely to have economic implications. The purpose of this review is to evaluate the effect of DAAs on extra hepatic manifestations of CHC virus infection. RECENT FINDINGS: Recent studies indicate that DAAs are associated with reduction in all-cause mortality, even in patients without significant hepatic fibrosis. They are also associated with reduction in incident cardiovascular disease and diabetes. DAAs are the mainstay of treatment in HCV-associated cryoglobulinemia and lymphoma. Successful HCV therapy with DAAs also improves patient-related outcomes such as health-related quality of life. DAAs improve extrahepatic manifestations of CHC virus infection. Future studies are needed to evaluate the long-term durability of treatment response and for accounting amelioration of extrahepatic manifestations into the cost effectiveness of DAA regimens.
PURPOSE OF REVIEW: Direct acting antiviral agents (DAAs) have emerged as simple, short, safe, and effective treatments for chronic hepatitis C (CHC) infection. CHC is a systemic disease with frequent and multiple extrahepatic manifestations. The beneficial effects of DAA treatment regimens extend beyond improvement in liver-related outcomes to amelioration of extra hepatic manifestations and are likely to have economic implications. The purpose of this review is to evaluate the effect of DAAs on extra hepatic manifestations of CHC virus infection. RECENT FINDINGS: Recent studies indicate that DAAs are associated with reduction in all-cause mortality, even in patients without significant hepatic fibrosis. They are also associated with reduction in incident cardiovascular disease and diabetes. DAAs are the mainstay of treatment in HCV-associated cryoglobulinemia and lymphoma. Successful HCV therapy with DAAs also improves patient-related outcomes such as health-related quality of life. DAAs improve extrahepatic manifestations of CHC virus infection. Future studies are needed to evaluate the long-term durability of treatment response and for accounting amelioration of extrahepatic manifestations into the cost effectiveness of DAA regimens.
Authors: Zobair M Younossi; Maria Stepanova; Linda Henry; Edward Gane; Ira M Jacobson; Eric Lawitz; David Nelson; Lynn Gerber; Fatema Nader; Sharon Hunt Journal: Clin Gastroenterol Hepatol Date: 2013-12-06 Impact factor: 11.382
Authors: Sharon M Moe; A J Pampalone; Susan Ofner; Marc Rosenman; Evgenia Teal; Siu L Hui Journal: Am J Kidney Dis Date: 2008-04-28 Impact factor: 8.860
Authors: P Cacoub; P Buggisch; J A Carrión; G S Cooke; A L Zignego; R Beckerman; Z Younossi Journal: J Viral Hepat Date: 2018-03-30 Impact factor: 3.728
Authors: Iman Ibrahim Salama; Hala M Raslan; Ghada A Abdel-Latif; Somaia I Salama; Samia M Sami; Fatma A Shaaban; Aida M Abdelmohsen; Walaa A Fouad Journal: World J Hepatol Date: 2022-06-27
Authors: Julia L Marcus; Michael J Silverberg; Jennifer O Lam; Leo B Hurley; Jennifer B Lai; Varun Saxena; Suk Seo; Scott Chamberland; Charles P Quesenberry; Jamila H Champsi; Joanna Ready; Elizabeth Y Chiao Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-09-28 Impact factor: 4.090
Authors: Giuseppe Scelza; Alessandra Amato; Antonio Maria Pagano; Giuseppe De Matteis; Rosa Caruso; Antonio Scelza; Laura Sisalli; Sebastiana De Biasi; Francesca Marigliano; Mario Gagliardi; Stefano Martina; Alfredo Iandolo Journal: Ann Gastroenterol Date: 2021-11-10